Chugai expects no impact on top seller Avastin following US breast cancer decision
This article was originally published in Scrip
Roche's Japanese subsidiary Chugai does not expect its continued sale of Avastin (bevacizumab) in Japan to be affected by the recent US FDA revocation of approval for the product in metastatic breast cancer.
You may also be interested in...
Given its ever-growing role as a critical component of the global biopharma industry, you can’t afford not to be up to speed on Asia. This biweekly selection of insights from our experienced on-the-ground team will help.
Plus deals involving LegoChem/Pyxix, Biohaven/Sosei Heptares, Kyowa Kirin/Helsinn, Dr. Reddy’s/Glenmark, Eisai/Wren, KoBioLabs/Kolmar Korea, Y-Biologics/Pierre Fabre, Generex/Chinese consortium.
Join us for a brief audio tour around the past week's major global biopharma industry developments, in this podcast version of Scrip's Five Must-Know Things.